Onco Wiki / Regime

Paclitaxel em monoterapia (sarcoma de Kaposi, pós-antraciclina)

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

Registro de base de conhecimento para auditoria. Conteúdo clínico provisório: não é uma prescrição. Um oncologista deve verificar fontes originais, aplicabilidade e estado de revisão. Regras completas e restrições estão no YAML.

Fonte YAML: registo completo

ComponentesDRUG-PACLITAXEL
IDREG-PACLITAXEL-KAPOSI
TipoEsquema terapêutico
Estadoreviewed 2026-07-11 | pending_clinical_signoff
DoençasNenhuma declaração
FontesNenhuma declaração

Notas

New Regimen entity reusing the existing DRUG-PACLITAXEL Drug entity. DRUG-PACLITAXEL already documents "Kaposi sarcoma (AIDS-related, 2L)" as an FDA-approved indication (regulatory_status.fda.indications_brief -- pre-existing fact, transcribed not invented, verified by direct read of drugs/paclitaxel.yaml during independent review) but its typical_dosing field does not carry a Kaposi-specific mg/m²/schedule figure, and no KB-verifiable primary source for that figure was available at authoring time. Per CHARTER §8.3 ("must NEVER invent a dose ..."), the `dose`/`schedule` component fields are deliberately left as an explicit flagged gap rather than a fabricated number -- this is an intentional, disclosed omission, not an authoring oversight. The mandatory Cremophor-EL hypersensitivity premedication IS transcribed from the existing DRUG-PACLITAXEL entity because that fact is dose-independent and already verified in the KB. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 for the dose-adjustment items and the file's top-level sources. That source documents only basal-cell/squamous- cell skin cancer (confirmed by direct inspection of its own KB reco...

Usado por

Doença

Indicação